✨ Medicines Distribution Consent




NEW ZEALAND GAZETTE

No. 36


Product:

Sequence Fluoride Rinse System – Tangy Tangerine Flavour

  • Satchet 1
    • Active Ingredient: Sodium fluoride 440mg/g
  • Satchet 2
    • Active Ingredient: Stannous fluoride 85mg/g
  • Dosage Form: Powder for mouthwash
  • New Zealand Sponsor: Ivoclar Vivadent Limited
  • Manufacturer: Pascal Company Inc, Bellevue, Washington, United States of America

Product:

Sequence Fluoride Rinse System

Fresh Mint component:

  • Satchet 1
    • Active Ingredient: Sodium fluoride 430mg/g
  • Satchet 2
    • Active Ingredient: Stannous fluoride 30mg/g

Tangy Tangerine Component:

  • Satchet 1
    • Active Ingredient: Sodium fluoride 440mg/g
  • Satchet 2
    • Active Ingredient: Stannous fluoride 85mg/g
  • Dosage Form: Powder for mouthwash
  • New Zealand Sponsor: Ivoclar Vivadent Limited
  • Manufacturer: Pascal Company Inc, Bellevue, Washington, United States of America

Product:

Strepsils Easy Breathing Vapour Ampoules

  • Active Ingredients:
    • Menthol 35.55mg
    • Pine needle oil 9mg
    • Pumilio pine oil 103.05mg
    • Terpineol 66.6mg
  • Dosage Form: Liquid filled inhalation capsule
  • New Zealand Sponsor: Boots Healthcare New Zealand Limited
  • Manufacturer: The Boots Company Plc., Beeston, Nottingham, United Kingdom

Product:

Zeffix

  • Active Ingredient: Lamivudine 5mg/mL
  • Dosage Form: Oral solution
  • New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
  • Manufacturers:
    • Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
    • GlaxoSmithKline Inc, Mississauga, Ontario, Canada

Product:

Zeffix

  • Active Ingredient: Lamivudine 100mg
  • Dosage Form: Film coated tablet
  • New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
  • Manufacturer: Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom

Dated this 3rd day of April 2003.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go2335


Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Product:
Efexor

  • Active Ingredient: Venlafaxine hydrochloride 42.4mg equivalent to 37.5mg venlafaxine base
  • Dosage Form: Tablet
  • New Zealand Sponsor: Wyeth (NZ) Limited
  • Manufacturers:
    • John Wyeth and Brother Limited, Havant, Hampshire, United Kingdom
    • Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia
    • Wyeth Medica Ireland, Little Connell, Newbridge, County Kildare, Ireland
    • Wyeth Pharmaceuticals Company, Barrios Pozo Hondos & Jobos, Guayama, Puerto Rico


Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2003, No 36


Gazette.govt.nz PDF NZ Gazette 2003, No 36





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
3 April 2003
Medicines Act, Distribution consent, New medicines, Sequence Fluoride Rinse System, Strepsils Easy Breathing Vapour Ampoules, Zeffix
  • G. R. Boyd, Chief Advisor, Safety and Regulation

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
Medicines Act, Distribution consent, Changed medicines, Efexor